MAPT and Alzheimer disease: A systematic review primarily on imaging and biochemical biomarkers, including primarily MRI, PET scans, and CSF or plasma amyloid-β/tau, with longitudinal cohorts in anticipating characterization of AD progression has been documented (Lawrence et al., 2017).